Deprecated: The each() function is deprecated. This message will be suppressed on further calls in /home/zhenxiangba/zhenxiangba.com/public_html/phproxy-improved-master/index.php on line 456
NZ771013B2 - Formulations of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methycyclohexylamino)-pyrimidine-5-carboxamide - Google Patents
[go: Go Back, main page]

NZ771013B2 - Formulations of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methycyclohexylamino)-pyrimidine-5-carboxamide - Google Patents

Formulations of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methycyclohexylamino)-pyrimidine-5-carboxamide Download PDF

Info

Publication number
NZ771013B2
NZ771013B2 NZ771013A NZ77101315A NZ771013B2 NZ 771013 B2 NZ771013 B2 NZ 771013B2 NZ 771013 A NZ771013 A NZ 771013A NZ 77101315 A NZ77101315 A NZ 77101315A NZ 771013 B2 NZ771013 B2 NZ 771013B2
Authority
NZ
New Zealand
Prior art keywords
salt
dosage form
crystalline
disorder
butylamino
Prior art date
Application number
NZ771013A
Other versions
NZ771013A (en
Inventor
Nathan Andrew Boersen
Indrajit Ghosh
Lianfeng Huang
Daozhong Zou
Original Assignee
Signal Pharmaceuticals Llc
Filing date
Publication date
Application filed by Signal Pharmaceuticals Llc filed Critical Signal Pharmaceuticals Llc
Priority claimed from NZ732793A external-priority patent/NZ732793A/en
Publication of NZ771013A publication Critical patent/NZ771013A/en
Publication of NZ771013B2 publication Critical patent/NZ771013B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms

Abstract

Provided are crystalline salts of 2-(tert-butylamino)-4-((1R,3R,4R)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide, wherein the crystalline salt is a hydrochloride salt, a sulfate salt, a phosphate salt, an L-tartrate salt, or an L-lactate salt, and pharmaceutical compositions and dosage forms thereof. Also provided are methods of treating, managing, or preventing various disorders, such as diseases or disorders treatable or preventable by inhibition of a JNK pathway in mammals using such crystalline salts, pharmaceutical compositions or dosage forms.

Claims (8)

What we claim is:
1. A crystalline salt of 2-(tert-butylamino)((1R,3R,4R)hydroxy methylcyclohexylamino)-pyrimidinecarboxamide, wherein the crystalline salt is a hydrochloride salt, a sulfate salt, a phosphate salt, an L-tartrate salt, or an L-lactate salt.
2. A pharmaceutical composition comprising the crystalline salt of claim 1.
3. A dosage form sing the crystalline salt of claim 1.
4. The pharmaceutical composition of claim 2 or the dosage form of claim 3, wherein said pharmaceutical composition or said dosage form is a tablet.
5. Use of the lline salt according to claim 1, the ceutical ition according to claim 2 or 4, or a dosage form according to claim 3 or 4 in the manufacture of a medicament for treating or preventing a disease or disorder treatable or preventable by inhibition of a JNK pathway.
6. The use of claim 5, n said e or disorder is selected from a group consisting of interstitial pulmonary fibrosis, systemic sclerosis, scleroderma, chronic allograft nephropathy, antibody mediated rejection and lupus.
7. The use of claim 5, wherein said disease or disorder is a liver fibrotic disorder, diabetes or a metabolic syndrome leading to liver fibrotic disorders.
8. A crystalline salt according to claim 1, substantially as herein described or exemplified.
NZ771013A 2015-12-15 Formulations of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methycyclohexylamino)-pyrimidine-5-carboxamide NZ771013B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462092537P 2014-12-16 2014-12-16
US201562196044P 2015-07-23 2015-07-23
NZ732793A NZ732793A (en) 2014-12-16 2015-12-15 Formulations of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methycyclohexylamino)-pyrimidine-5-carboxamide

Publications (2)

Publication Number Publication Date
NZ771013A NZ771013A (en) 2024-05-31
NZ771013B2 true NZ771013B2 (en) 2024-09-03

Family

ID=

Similar Documents

Publication Publication Date Title
WO2017087608A8 (en) Modulators of ror-gamma
SA517381749B1 (en) Formulations of 2-(Tert-Butylamino)-4-((1r,3r,4r)-3-Hydroxy-4-Methylcyclohexylamino)-Pyrimidine-5-Carboxamide
WO2014179564A8 (en) Thiazolopyrrolidine inhibitors of ror-gamma
WO2017132432A8 (en) Benzimidazole derivatives as modulators of ror-gamma
CL2013003025A1 (en) Compounds derived from diaminocarboxamide and diaminocarbonitrile pyrimidines, such as jnk kinase inhibitors; pharmaceutical composition; in vitro inhibition method; and its use in the treatment or prevention of fibrotic liver disorders, diabetes or metabolic syndrome leading to fibrotic liver disorders.
TN2019000281A1 (en) Ferroportin-inhibitor salts
AR094374A1 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC DISORDERS
WO2017068089A9 (en) Ferroportin inhibitors
ME02150B (en) Piperidinone derivatives as mdm2 inhibitors for the treatment of cancer
JP2015038135A5 (en)
HK1206264A1 (en) Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
ME02390B (en) Beta-secretase INHIBITORS
WO2016172496A8 (en) Lsd1 inhibitors and uses thereof
CU20180131A7 (en) N- {6- (2-HYDROXIPROPAN-2-IL) -2- [2- (METILSULFONIL) ETHYL] -2H-INDAZOL-5-IL} -6- (TRIFLUOROMETIL) PIRIDIN-2-CARBOXAMIDE
NZ715903A (en) Solid forms of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide, compositions thereof and methods of their use
BR112017007428A2 (en) fatty acid and self-fatty acid ester compositions and their uses in the treatment of disease states
WO2015116856A3 (en) Farnesoid x receptor antagonists
PH12021550170A1 (en) Pharmaceutical dosage form which can be adminitered orally and has modified release
WO2014130752A3 (en) Bicyclic compounds
WO2016168553A8 (en) Deuterated obeticholic acid
CO2020006789A2 (en) Procedure for the preparation of (3s) -3- (4-chloro-3 - {[(2s, 3r) -2- (4-chlorophenyl) -4,4,4-trifluoro-3-methylbutanoyl] amino} phenyl) -3-cyclopropylpropanoic acid and its crystalline form for use as an active pharmaceutical ingredient
AR117614A1 (en) ORAL ADMINISTRABLE PHARMACEUTICAL DOSAGE FORM WITH MODIFIED RELEASE
NZ771013B2 (en) Formulations of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methycyclohexylamino)-pyrimidine-5-carboxamide
NZ630746A (en) Vitamins c and k for treating polycystic diseases
HK1238638A1 (en) Formulations of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methycyclohexylamino)-pyrimidine-5-carboxamide